The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study.
AFP
ALBI grade
bone metastasis
hepatocellular carcinoma
lenvatinib
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
26 May 2021
26 May 2021
Historique:
received:
14
03
2021
revised:
29
04
2021
accepted:
07
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Lenvatinib (LEN) has been approved for patients with unresectable hepatocellular carcinoma (u-HCC) since March 2018 in Japan. We performed a retrospective nationwide multicenter study to clarify the clinical characteristics of LEN in real-world practice. A total of 343 u-HCC patients who received LEN from March 2018 to May 2020 at 23 sites in Japan were registered. During the median observation period of 10.5 months, 143 patients died. In Child-Pugh A ( LEN showed a high response rate in real-world practice. Pretreatment factors, including ALBI score, AFP, and major vascular invasion are important in making a treatment strategy for patients with u-HCC. The patients with bone metastasis would be candidates for new therapeutic approaches.
Sections du résumé
BACKGROUND
BACKGROUND
Lenvatinib (LEN) has been approved for patients with unresectable hepatocellular carcinoma (u-HCC) since March 2018 in Japan. We performed a retrospective nationwide multicenter study to clarify the clinical characteristics of LEN in real-world practice.
METHODS
METHODS
A total of 343 u-HCC patients who received LEN from March 2018 to May 2020 at 23 sites in Japan were registered.
RESULTS
RESULTS
During the median observation period of 10.5 months, 143 patients died. In Child-Pugh A (
CONCLUSION
CONCLUSIONS
LEN showed a high response rate in real-world practice. Pretreatment factors, including ALBI score, AFP, and major vascular invasion are important in making a treatment strategy for patients with u-HCC. The patients with bone metastasis would be candidates for new therapeutic approaches.
Identifiants
pubmed: 34073396
pii: cancers13112608
doi: 10.3390/cancers13112608
pmc: PMC8198233
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Japan Agency for Medical Research and Development
ID : JP19fk0210025h0003
Références
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Oncotarget. 2019 Jun 18;10(40):4018-4025
pubmed: 31258846
Urol Oncol. 2020 Aug;38(8):686.e1-686.e9
pubmed: 32430250
Liver Cancer. 2017 Nov;6(4):325-336
pubmed: 29234636
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Mol Cell Biol Res Commun. 1999 Sep-Dec;2(3):155-61
pubmed: 10662591
Cancers (Basel). 2020 Apr 19;12(4):
pubmed: 32325921
J Natl Compr Canc Netw. 2018 Jan;16(1):50-58
pubmed: 29295881
PLoS One. 2020 Apr 10;15(4):e0231427
pubmed: 32275701
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Clin Oncol. 2020 Jan 20;38(3):193-202
pubmed: 31790344
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Laryngoscope. 2021 Jun;131(6):E1838-E1846
pubmed: 33098338
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Cancer Med. 2019 Jul;8(8):3719-3728
pubmed: 31127698
PLoS One. 2020 Apr 20;15(4):e0231828
pubmed: 32310967
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Cell. 2019 Nov 14;179(5):1177-1190.e13
pubmed: 31730856
Br J Surg. 1973 Aug;60(8):646-9
pubmed: 4541913
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Cancers (Basel). 2019 Jul 07;11(7):
pubmed: 31284682